Xceleron, a provider of analytical strategies for drug development, will expand its U.S. business by signing of a lease on a facility in Germantown, MD. The facility, opening in November 2007, will house a new accelerator mass spectrometer (AMS) and employ at least 20 people in scientific, commercial and administrative roles. Professor Colin Garner, Xceleron’s chief executive officer, commented, “This is a major strategic development in the evolution of our company. We will invest...